|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Importance of physical capacity and the effects of exercise in heart transplant recipients显示文摘One of the most important prognostic factors in heart failure patients is physical capacity. Patients with very poor physical performance and otherwise eligible, may be listed as candidates for heart transplantation(HTx). After such surgery, life-long immunosuppression therapy is needed to prevent rejection of the new heart. The dark side of immunosuppression is the increased risk of infections, kidney failure, cancer and advanced atherosclerosis(cardiac allograft vasculopathy), with the two latter conditions as the main causes of later mortality. In a worldwide perspective, 50% of the HTx patients survive past 10 years. Poor aerobic capacity prior to graft deterioration is not only limited to the failing heart, but also caused by peripheral factors, such as limited function in the skeletal muscles and in the blood vessels walls. Exercise rehabilitation after HTx is of major importance in order to improve physical capacity and prognosis. Effects of high-intensity interval training(HIT) in HTx recipients is a growing field of research attracting worldwide focus and interest. Accumulating evidence has shown that HIT is safe and efficient in maintenance HTx recipients; with superior effects on physical capacity compared to conventional moderate exercise. This article generates further evidence to the field by summarizing results from a decade of research performed at our center supported by a broad, but not strict formal, literature review. In short, this article demonstrates a strong association between physical capacity measured after HTx and long-term survival. It describes the possible 'HITeffect' with increased levels of inflammatory mediators of angiogenesis. It also describes long-term effects of HIT; showing a positive effect in development of anxiety symptoms despite that the improved physical capacity was not sustained, due to downregulation ofexercise and intensity. Finally, our results are linked to the ongoing HITTS study, which investigates safety and efficiency of HIT in de novo HTx recipients. Together with previous results, this study may have the potential to change existing guidelines and contribute to a better prognosis for the HTx population as a whole. | Marianne Yardley Lars Gullestad Kari Nytr?en | 2018 | World Journal of Transplantation2018，8，1： | 6 |
| 2 | Atherosclerotic Plaque Stability—What Determines the Fate of a Plaque?显示文摘 | Bente Halvorsen Kari Otterdal Tuva B. Dahl Mona Skjelland Lars Gullestad Erik ?ie P?l Aukrust | 2008 | Progress in Cardiovascular Diseases2008，，3： | 1 |
| 3 | Inflammatory and anti-inflam- matory cytokines in chronic heart failure:potential therapeutic implica- tions 显示文摘 | Aukrust P Gullestad L Ueland T | 2005 | Annals of Medicine2005，37，： | 1 |
| 4 | Immunonodulating therapy with intravenous immunoglobulin in patients with chromic heart failure 显示文摘 | Gullestad L Aass H Fjed JG | 2001 | Circulation2001，103，： | 1 |
| 5 | Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart Failure Data From CORONA and COACH 显示文摘 | van der Velde AR Gullestad L Ueland T | 2013 | Circ Heart Fail2013，6，2： | 1 |
| 6 | Inflammatory Cytokines in Heart Failure: Mediators and Markers显示文摘 | Gullestad L Ueland T Vinge L E | 2012 | Cardiology2012，122，1： | 1 |
| 7 | CXC-chemokines, a new group of cytokines in congestive heart failure-possible role of platelets and monocytes显示文摘 | Damas JK Gullestad L Ueland T | 2000 | Cardiovasc Res2000，45，： | 1 |
| 8 | Intravenous immunoglobulin does not reduce left ventricular remodeling in patients with myocardial dysfunction during hospitalization after acute myocardial infarction显示文摘 | Lars Gullestad Stein ?rn Kenneth Dickstein Christian Eek Thor Edvardsen Svend Aakhus Erik T. Askevold Annika Michelsen Bj?rn Bendz Rita Sk?rdal Hans-J?rgen Smith Arne Yndestad Thor Ueland P?l Aukrust | 2012 | International Journal of Cardiology2012，，： | 1 |
| 9 | NT-proBNP predicts myocardial recovery after non-ST-elevation acute coronary syndrome显示文摘 | Kaspar Broch Christian Eek Ragnhild Wergeland Thor Ueland Rita Sk? rdal P? l Aukrust Helge Skulstad Lars Gullestad | 2012 | Scandinavian Cardiovascular Journal2012，，2： | 1 |
| 10 | Inflammatory cytokines in heart failure: mediators and markers 显示文摘 | Gullestad L Ueland T Vinge LE | 2012 | Cardiology2012，122，1： | 1 |
| 11 | Imunmomodulating therapy with intravenaus immunoglobulin in patients with chronic heartfailure显示文摘 | Gullestad L Aass H Fjeld JG | 2001 | Circulation2001，103，2： | 1 |
| 12 | Complement activationin patients with congestive heart failure:effect of high-dose intravenousimmunoglobulin treatment显示文摘 | Aukrust P Gullestad L Lappeg-rd KT | 2001 | Circulation2001，104，13： | 1 |
| 13 | Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure显示文摘 | Aass H Field JG | 2001 | Circulation2001，103，： | 1 |
| 14 | Neuropeptide Y receptor l (NPY-Y1) expression in human heart failure and heart transplantation显示文摘 | I Gullestad L Aass H Ross H eta/ | 1998 | Auton Nerv Syst1998，70，2： | 1 |
| 15 | Agents targeting inflammation in heart failure显示文摘 | Gullestad L Kjekshus J Damas JK | 2005 | Expert Opin Investig Drugs2005，14，5： | 1 |
| 16 | Cytokines as new treatment targets in chronic heart failure显示文摘 | Damas JK Gullestad L Aukrust P | 2001 | Curr Control Trials Cardiovasc Med2001，2，： | 1 |
| 17 | Effects of hish-versus low-dose angiotensin converting enzyme inhibitor on cytokine levels in chronic heart failure 显示文摘 | Gullestad L Aukrust P Ueland T | 1999 | J Am Coll Cardiol1999，34，7： | 1 |
| 18 | The cytokine network in heart failure: pathogenetic importance and potential therapeutic targets显示文摘 | Gullestad L Aukrust P | 2001 | Heart Fail Monit2001，2，1： | 1 |
| 19 | Effects of statin therapy according to plasma hlgh-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) : a retrospective analysis显示文摘 | McMurray JJ Kjekshas J Gullestad L | 2009 | Circulation2009，120，22： | 1 |
| 20 | MERIT- HF Study Group, What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF) 显示文摘 | GULLESTAD L WIKSTRAND J DEEDWANIA P | 2005 | J Am Coil Cardiol2005，45，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员